SCHEMBL4097314

SCHEMBL4097314

CCOC(=O)N1CCN(c2nc(Cc3ccccc3C)nc3ccccc23)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.59
MEN1 O00255 8/20 0.59
SMN1; SMN2 Q16637 3/20 0.49
POLB P06746 1/20 0.49
ADRB2 P07550 1/20 0.49
GBA1 P04062 1/20 0.48
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.46
ATM Q13315 1/20 0.46
HTR3E A5X5Y0 1/20 0.46
HTR3B O95264 1/20 0.46
HTR3A P46098 1/20 0.46
HTR3D Q70Z44 1/20 0.46
HTR3C Q8WXA8 1/20 0.46
USP2 O75604 1/20 0.45
CASP1 P29466 1/20 0.45
HBB P68871 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089290 0.91 KMT2A (0.58) KMT2AMEN1SMN1; SMN2POLBADRB2
SCHEMBL4754030 0.91 KMT2A (0.58) KMT2AMEN1SMN1; SMN2POLBADRB2
SCHEMBL4085104 0.82 ALDH1A1 (0.60) KMT2AMEN1GBA1ALDH1A1HTR3E
SCHEMBL4096964 0.82 MEN1 (0.57) KMT2AMEN1GBA1ALDH1A1GAA
SCHEMBL4089697 0.81 MEN1 (0.55) KMT2AMEN1SMN1; SMN2POLBADRB2
SCHEMBL4103685 0.78 MEN1 (0.57) KMT2AMEN1SMN1; SMN2POLBADRB2
SCHEMBL1084085 0.75 MEN1 (0.67) KMT2AMEN1POLBADRB2GBA1
SCHEMBL4095953 0.75 MEN1 (0.67) KMT2AMEN1POLBADRB2GBA1
SCHEMBL4096171 0.75 MEN1 (0.67) KMT2AMEN1SMN1; SMN2POLBADRB2
SCHEMBL4095930 0.73 MEN1 (0.66) KMT2AMEN1SMN1; SMN2POLBADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 KMT2A 1424/4885MEN1 718/4885SMN1; SMN2 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.